N-[2-(5-phenylsulfanylpyridin-3-yl)-2-azabicyclo[3.1.0]hex-3-ylmethyl]methylamine fumarate | 1313815-25-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-[2-(5-phenylsulfanylpyridin-3-yl)-2-azabicyclo[3.1.0]hex-3-ylmethyl]methylamine fumarate
• 英文别名: (E)-but-2-enedioic acid;N-methyl-1-[2-(5-phenylsulfanylpyridin-3-yl)-2-azabicyclo[3.1.0]hexan-3-yl]methanamine
• CAS: 1313815-25-6
• 化学式: C₄H₄O₄*C₁₈H₂₁N₃S
• 分子量: 427.524
• InChiKey: KLLGDUNYBIXENV-WLHGVMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.13
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  128
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Alpha 4 Beta 2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Nirogi Ramakrishna

  公开号：US20120322808A1

  公开（公告）日：2012-12-20

  The present invention relates to novel α 4 β 2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. The present invention relates to novel α4β2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them.

  本发明涉及公式（I）的新型α4β2神经元尼古丁乙酰胆碱受体配体化合物，以及它们的衍生物、立体异构体、药用可接受盐和含有它们的组合物。
• ALPHA4BETA2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Suven Life Sciences Limited

  公开号：EP2519514A2

  公开（公告）日：2012-11-07
• US8653071B2
  申请人：——

  公开号：US8653071B2

  公开（公告）日：2014-02-18
• [EN] a4ß2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RÉCEPTEUR NICOTINIQUE NEURONAL DE L'ACÉTYLCHOLINE ?4?2
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2011080751A2

  公开（公告）日：2011-07-07

  The present invention relates to novel α4β2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. The present invention relates to novel α4β2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them.